291 related articles for article (PubMed ID: 20231034)
1. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.
Rasmussen K; Maeng M; Kaltoft A; Thayssen P; Kelbaek H; Tilsted HH; Abildgaard U; Christiansen EH; Engstrøm T; Krusell LR; Ravkilde J; Hansen PR; Hansen KN; Abildstrøm SZ; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Madsen M; Johnsen SP; Jensen LO; Sørensen HT; Thuesen L; Lassen JF;
Lancet; 2010 Mar; 375(9720):1090-9. PubMed ID: 20231034
[TBL] [Abstract][Full Text] [Related]
2. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.
Maeng M; Tilsted HH; Jensen LO; Krusell LR; Kaltoft A; Kelbæk H; Villadsen AB; Ravkilde J; Hansen KN; Christiansen EH; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Thuesen L; Madsen M; Thayssen P; Sørensen HT; Lassen JF
Lancet; 2014 Jun; 383(9934):2047-2056. PubMed ID: 24631162
[TBL] [Abstract][Full Text] [Related]
3. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
von Birgelen C; Sen H; Lam MK; Danse PW; Jessurun GA; Hautvast RW; van Houwelingen GK; Schramm AR; Gin RM; Louwerenburg JW; de Man FH; Stoel MG; Löwik MM; Linssen GC; Saïd SA; Nienhuis MB; Verhorst PM; Basalus MW; Doggen CJ; Tandjung K
Lancet; 2014 Feb; 383(9915):413-23. PubMed ID: 24183564
[TBL] [Abstract][Full Text] [Related]
4. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
5. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial.
Silber S; Windecker S; Vranckx P; Serruys PW;
Lancet; 2011 Apr; 377(9773):1241-7. PubMed ID: 21459430
[TBL] [Abstract][Full Text] [Related]
6. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
Christiansen EH; Jensen LO; Thayssen P; Tilsted HH; Krusell LR; Hansen KN; Kaltoft A; Maeng M; Kristensen SD; Bøtker HE; Terkelsen CJ; Villadsen AB; Ravkilde J; Aarøe J; Madsen M; Thuesen L; Lassen JF;
Lancet; 2013 Feb; 381(9867):661-9. PubMed ID: 23374649
[TBL] [Abstract][Full Text] [Related]
7. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
von Birgelen C; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Gin RMTJ; Somi S; van Houwelingen KG; Stoel MG; de Man FHAF; Louwerenburg JHW; Hartmann M; Zocca P; Linssen GCM; van der Palen J; Doggen CJM; Löwik MM
Lancet; 2016 Nov; 388(10060):2607-2617. PubMed ID: 27806902
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV).
Jensen LO; Thayssen P; Hansen HS; Christiansen EH; Tilsted HH; Krusell LR; Villadsen AB; Junker A; Hansen KN; Kaltoft A; Maeng M; Pedersen KE; Kristensen SD; Bøtker HE; Ravkilde J; Sanchez R; Aarøe J; Madsen M; Sørensen HT; Thuesen L; Lassen JF;
Circulation; 2012 Mar; 125(10):1246-55. PubMed ID: 22308301
[TBL] [Abstract][Full Text] [Related]
9. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.
Sabate M; Cequier A; Iñiguez A; Serra A; Hernandez-Antolin R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vazquez N; Gómez-Hospital JA; Baz JA; Martin-Yuste V; van Geuns RJ; Alfonso F; Bordes P; Tebaldi M; Masotti M; Silvestro A; Backx B; Brugaletta S; van Es GA; Serruys PW
Lancet; 2012 Oct; 380(9852):1482-90. PubMed ID: 22951305
[TBL] [Abstract][Full Text] [Related]
10. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
[TBL] [Abstract][Full Text] [Related]
11. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
Serruys PW; Silber S; Garg S; van Geuns RJ; Richardt G; Buszman PE; Kelbaek H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Ronden J; Bressers M; Gobbens P; Negoita M; van Leeuwen F; Windecker S
N Engl J Med; 2010 Jul; 363(2):136-46. PubMed ID: 20554978
[TBL] [Abstract][Full Text] [Related]
12. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial.
Camenzind E; Wijns W; Mauri L; Kurowski V; Parikh K; Gao R; Bode C; Greenwood JP; Boersma E; Vranckx P; McFadden E; Serruys PW; O'Neil WW; Jorissen B; Van Leeuwen F; Steg PG;
Lancet; 2012 Oct; 380(9851):1396-405. PubMed ID: 22951082
[TBL] [Abstract][Full Text] [Related]
13. Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy.
Thim T; Maeng M; Kaltoft A; Jensen LO; Tilsted HH; Hansen PR; Kelbaek H; Thayssen P; Ravkilde J; Madsen M; Sørensen HT; Thuesen L; Lassen JF
Eur J Clin Invest; 2012 Oct; 42(10):1047-54. PubMed ID: 22624990
[TBL] [Abstract][Full Text] [Related]
14. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial.
Windecker S; Serruys PW; Wandel S; Buszman P; Trznadel S; Linke A; Lenk K; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; Davies S; van Geuns RJ; Eerdmans P; van Es GA; Meier B; Jüni P
Lancet; 2008 Sep; 372(9644):1163-73. PubMed ID: 18765162
[TBL] [Abstract][Full Text] [Related]
15. A randomized, prospective, two-center comparison of sirolimus-eluting stent and zotarolimus-eluting stent in acute ST-elevation myocardial infarction: the SEZE trial.
Chung WY; Kang J; Cho YS; Park HJ; Yang HM; Seo JB; Suh JW; Kim KI; Youn TJ; Kim SH; Chae IH; Zo JH; Kim MA; Choi DJ
Chin Med J (Engl); 2012 Oct; 125(19):3373-81. PubMed ID: 23044291
[TBL] [Abstract][Full Text] [Related]
16. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial.
Kedhi E; Joesoef KS; McFadden E; Wassing J; van Mieghem C; Goedhart D; Smits PC
Lancet; 2010 Jan; 375(9710):201-9. PubMed ID: 20060578
[TBL] [Abstract][Full Text] [Related]
17. Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial.
Raungaard B; Jensen LO; Tilsted HH; Christiansen EH; Maeng M; Terkelsen CJ; Krusell LR; Kaltoft A; Kristensen SD; Bøtker HE; Thuesen L; Aarøe J; Jensen SE; Villadsen AB; Thayssen P; Veien KT; Hansen KN; Junker A; Madsen M; Ravkilde J; Lassen JF;
Lancet; 2015 Apr; 385(9977):1527-35. PubMed ID: 25601789
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
19. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial.
Massberg S; Byrne RA; Kastrati A; Schulz S; Pache J; Hausleiter J; Ibrahim T; Fusaro M; Ott I; Schömig A; Laugwitz KL; Mehilli J;
Circulation; 2011 Aug; 124(5):624-32. PubMed ID: 21768546
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
